JP Morgan Chase’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-24
| Closed | -$3 | – | 7848 |
|
|
2024
Q1 | $3 | Hold |
24
| – | – | ﹤0.01% | 7305 |
|
|
2023
Q4 | $3 | Hold |
24
| – | – | ﹤0.01% | 7465 |
|
|
2023
Q3 | $4 | Sell |
24
-660
| -96% | -$820 | ﹤0.01% | 7387 |
|
|
2023
Q2 | $2.13K | Buy |
684
+660
| +2,750% | +$1.96K | ﹤0.01% | 6326 |
|
|
2023
Q1 | $0 | Hold |
24
| – | – | ﹤0.01% | 7350 |
|
|
2022
Q4 | $0 | Hold |
24
| – | – | ﹤0.01% | 7126 |
|
|
2022
Q3 | $0 | Hold |
24
| – | – | ﹤0.01% | 6968 |
|
|
2022
Q2 | $0 | Hold |
24
| – | – | ﹤0.01% | 7007 |
|
|
2022
Q1 | $0 | Hold |
24
| – | – | ﹤0.01% | 7128 |
|
|
2021
Q4 | $0 | Sell |
24
-27
| -53% | -$89 | ﹤0.01% | 7050 |
|
|
2021
Q3 | $0 | Sell |
51
-35,922
| -100% | -$308K | ﹤0.01% | 6901 |
|
|
2021
Q2 | $353K | Buy |
35,973
+12,319
| +52% | +$100K | ﹤0.01% | 4918 |
|
|
2021
Q1 | $209K | Buy |
23,654
+1,090
| +5% | +$12K | ﹤0.01% | 5129 |
|
|
2020
Q4 | $231K | Buy |
22,564
+16,332
| +262% | +$179K | ﹤0.01% | 4765 |
|
|
2020
Q3 | $54K | Sell |
6,232
-832
| -12% | -$6.59K | ﹤0.01% | 4918 |
|
|
2020
Q2 | $50K | Buy |
7,064
+4,236
| +150% | +$45K | ﹤0.01% | 4826 |
|
|
2020
Q1 | $27K | Buy |
2,828
+609
| +27% | +$7.85K | ﹤0.01% | 4885 |
|
|
2019
Q4 | $29K | Buy |
+2,219
| New | +$27.1K | ﹤0.01% | 5261 |
|
Other funds holding GRTX
JP Morgan Chase's GRTX Position: Q2 2024 in Review
JP Morgan Chase sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2024, closing a stake of 24 shares — an estimated $3 sold.
JP Morgan Chase first reported a position in GRTX in Q4 2019 and held it in 18 quarters. The position peaked at $353K in Q2 2021. 1 fund tracked by Wall St. Rank holds GRTX as of Q2 2024.
- JP Morgan Chase reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- JP Morgan Chase sold 24 Galera Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $3.
- JP Morgan Chase first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 18 quarters.
- JP Morgan Chase's Galera Therapeutics, Inc. Common Stock position peaked at $353K in Q2 2021.
- 1 fund tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2024.
Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.